Table 1.
Effects of Buprenorphine, Naltrexone, UFP-101, or Their Combinations on Food and Water Intake in Marchigian Sardinian Alcohol-Preferring Rats
| Treatment | Food Intake (min) |
Water Intake (min) |
|||||
|---|---|---|---|---|---|---|---|
| 30 | 60 | 120 | 30 | 60 | 90 | 120 | |
| Buprenorphine (mg/kg, IP) | |||||||
| Veh | 2.9 ± .5 | 4 ± .6 | 5.9 ± .9 | .1 ± 0 | .1 ± 0 | .1 ± .4 | .1 ± .4 |
| Bup .03 | 2.5 ± .6 | 2.9 ± .6 | 8.6 ± .9 | — | — | — | — |
| Bup .3 | 1.3 ± .5 | 3.8 ± 1.1 | 6.6 ± 1.7 | — | — | — | .1 ± 0 |
| Bup 3 | 1 ± .3 | 3 ± .6 | 7.5 ± 1.1 | — | — | — | — |
| Bup 6 | .5 ± .2a | 1.1 ± .4a | 2.1 ± .7a | — | — | — | .1 ± 0 |
| Naltrexone (mg/kg, IP) | |||||||
| Veh | 1.1 ± .5 | 1.6 ± .5 | 4.3 ± 1.1 | .4 ± .3 | .5 ± .3 | .5 ± .3 | .8 ± .3 |
| Nltx .25 | 1.4 ± .8 | 1.9 ± .8 | 3.1 ± .9 | .1 ± 0 | — | .7 ± .3 | 1.3 ± .4 |
| Nltx 1 | .7 ± .5 | .8 ± .5 | 3.3 ± .9 | .4 ± .4 | .5 ± .4 | .5 ± .4 | .6 ± .4 |
| Nltx 2.5 | 1.5 ± 1 | 3.1 ± 1.2 | 4.5 ± 1.2 | .2 ± .2 | .4 ± .4 | .7 ± .6 | .8 ± .7 |
| UFP-101 (μg/rat, ICV) | |||||||
| Veh | 2.7 ± .9 | 3.8 ± 1 | 8.2 ± .9 | .9 ± .9 | .9 ± .9 | 1.4 ± 1.4 | 1.4 ± 1.4 |
| UFP-101 5 | 5 ± 1.2 | 5.5 ± .7 | 7.3 ± 1.1 | 2.3 ± 1.5 | 2.3 ± 1.4 | 2.4 ± 1.4 | 3.2 ± 1.9 |
| UFP-101 10 | 2.2 ± .8 | 3 ± .7 | 5.6 ± 1.5 | 1.1 ± .8 | 1.3 ± .8 | 2.4 ± 1.7 | 2.4 ± 1.7 |
| UFP-101 20 | 4.3 ± 1.2 | 5 ± .9 | 6.8 ± 1.5 | — | .4 ± .4 | .4 ± .4 | 1.5 ± 1.5 |
| Naltrexone (mg/kg, IP) + Buprenorphine .03 (mg/kg, IP) | |||||||
| Veh + Veh | 1.4 ± .8 | 2.8 ± 1.3 | 1.7 ± .8 | — | — | — | — |
| Veh + Bup .03 | 2.4 ± 1 | 5 ± 1.1 | 2.7 ± 1 | — | — | — | 0 ± .2 |
| Nltx .25 + Bup .03 | 2.7 ± 1.1 | 4.8 ± 1.3 | 2.8 ± 1.1 | — | — | — | .1 ± 0 |
| Nltx .25 + Veh | 2.1 ± 1.7 | 2.3 ± .7 | 2 ± .7 | — | — | .1 ± .0 | .3 ± .1 |
| Naltrexone (mg/kg, IP) + Buprenorphine 3 (mg/kg, IP) | |||||||
| Veh + Veh | 3.5 ± 1.3 | 3.8 ± 1.3 | 4.7 ± 1.1 | .2 ± .2 | .4 ± .4 | .6 ± .4 | .6 ± .4 |
| Veh + Bup 3 | .2 ± .2 | .7 ± .6 | 1.9 ± 1.1 | .1 ± 0 | .2 ± .1 | .4 ± .2 | .5 ± .3 |
| Nltx .25 + Bup 3 | .7 ± .5 | 1.2 ± .9 | 2.8 ± 1.7 | .2 ± .1 | .3 ± .1 | .7 ± .2 | .8 ± .2 |
| Nltx .25 + Veh | 2.4 ± 1.1 | 2.6 ± 1.1 | 4.5 ± 1.4 | — | — | .1 ± 0 | .1 ± 0 |
| UFP-101 (μg/rat, ICV) + Buprenorphine 3 (mg/kg, IP) | |||||||
| Veh + Veh | 2.3 ± .9 | 3.3 ± .8 | 5.50 ± 1.5 | .1 ± 0 | .1 ± 0 | .1 ± 0 | .1 ± .1 |
| Veh + Bup 3 | .8 ± .4 | 1.5 ± .9 | 2.86 ± 1.5 | .2 ± 0 | .3 ± .3 | .3 ± .3 | .4 ± .4 |
| UFP 10 + Bup 3 | 3.4 ± .7 | 5.3 ± 1.2 | 7.34 ± 1.6 | .8 ± .7 | .9 ± .8 | 1 ± .9 | 1.1 ± 1 |
| UFP 20 + Bup 3 | 2.6 ± .5 | 4.2 ± 1.1 | 6.84 ± 1.6 | .1 ± 0 | .2 ± .2 | .2 ± .2 | .3 ± .3 |
IP, intraperitoneal; Veh, vehicle; Bup, buprenorphine; Nltx, naltrexone; UFP, UFP-101; ICV, intracerebroventricular. Treatments were conducted as described above for the respective experiments. Each value represents the mean (± SEM) of intake corrected for body weight (g/kg).
a
p < .01, difference from vehicle.